Novostia, a pioneering medical technology company, is thrilled to announce the successful completion of all planned implantations in its First-In-Human (FIH) Clinical study PILATUS (ClinicalTrials ID: NCT06119607). All ten patients have been successfully implanted with the groundbreaking TRIFLO Heart Valve, marking a significant achievement in the ongoing clinical trial. The surgical operations, conducted between December 2023 and May 2024, have been highly successful. The surgeons and medical teams have expressed their satisfaction with the TRIFLO Heart Valve, noting its promising performance and the excellent condition of the patients post-surgery.
Positive Early Results and Future Outlook
Initial results from the ongoing trial confirm the device’s good performance, with patients showing remarkable recovery and well-being. The TRIFLO Heart Valve, designed to revolutionize aortic heart valve replacement, has demonstrated significant improvements in patient conditions, and reduction in symptoms. This innovation aims to eliminate the need for lifelong anticoagulation therapy, thereby reducing associated risks and enhancing patient quality of life by addressing issues such as noise-induced discomfort.